Immune activation and coronary atherosclerosis in HIV-infectedwomen: Where arewe now, and wherewillwe go next?

Journal of Infectious Diseases

Volumn 208, Issue 11, 2013, Pages 1729-1731

  Boccara, Franck ^a   Cohen, Ariel ^b  

^a HÔPITAL SAINT ANTOINE   (France)

^b INSERM   (France)

Author keywords

Atherosclerosis; Coronary artery disease; Hiv

Indexed keywords

C REACTIVE PROTEIN;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUSE OF DEATH; CD4+ T LYMPHOCYTE; CELL ACTIVATION; CHRONIC KIDNEY FAILURE; COCAINE DEPENDENCE; CONGESTIVE HEART FAILURE; CORONARY ARTERY ATHEROSCLEROSIS; CYTOKINE PRODUCTION; DIABETES MELLITUS; DYSLIPIDEMIA; HEART INFARCTION; HEREDITY; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HYPERTENSION; IMMUNE ACTIVATION; IMMUNE RESPONSE; IMMUNOCOMPROMISED PATIENT; INFECTION RISK; INNATE IMMUNITY; MICROALBUMINURIA; MONOCYTE; MORBIDITY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SMOKING; SUDDEN CARDIAC DEATH; VIRUS LOAD;

ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; HIV;

CARDIOVASCULAR DISEASES; CORONARY ARTERY DISEASE; FEMALE; HIV; HIV INFECTIONS; HUMANS; MALE; PLAQUE, ATHEROSCLEROTIC;

EID: 84888586838     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jit511     Document Type: Review

References (22)

1. Boccara F, Lang S, Meuleman C, et al. HIV and coronary heart disease: Time for a better understanding. J Am Coll Cardiol 2013; 61:511-23.
2. Sliwa K, Carrington MJ, Becker A, Thienemann F, Ntsekhe M, Stewart S. Contribution of the human immunodeficiency virus/acquired immunodeficiency syndrome epidemic to de novo presentations of heart disease in the Heart of Soweto Study cohort. Eur Heart J 2012; 33:866-74.
3. Freiberg MS, Chang CC, Kuller LH, et al. HIV infection and the risk of acute myocardial infarction. JAMA Intern Med 2013; 173:614-22.
4. Rotger M, Glass TR, Junier T, et al. Contribution of genetic background, traditional risk factors, and HIV-related factors to coronary artery disease events in HIV-positive persons. Clin Infect Dis 2013; 57:112-21.
5. El-Sadr WM, Lundgren JD, Neaton JD, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355:2283-96.
6. Triant VA, Meigs JB, Grinspoon SK. Association of C-reactive protein and HIV infection with acute myocardial infarction. J Acquir Immune Defic Syndr 2009; 51:268-73.
7. Lang S, Mary-Krause M, Simon A, et al. HIV replication and immune status are independent predictors of the risk of myocardial infarction in HIV-infected individuals. Clin Infect Dis 2012; 55:600-7.
8. Mosca L, Barrett-Connor E, Wenger NK. Sex/gender differences in cardiovascular disease prevention: what a difference a decade makes. Circulation 2011; 124:2145-54.
9. Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab 2007; 92:2506-12.
10. Lang S, Mary-Krause M, Cotte L, et al. Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: A case-control study nested within the French Hospital Database on HIV ANRS cohort CO4. Arch Intern Med 2010; 170:1228-38.
11. Kaplan RC, Kingsley LA, Sharrett AR, et al. Ten-year predicted coronary heart disease risk in HIV-infected men and women. Clin Infect Dis 2007; 45:1074-81.
12. Fitch KV, Srinivasa S, Abbara S, et al. Noncalcified coronary atherosclerotic plaque and immune activation in HIV-infected women. J Infect Dis 2013; 208:1737-46.
13. Lo J, Abbara S, Shturman L, et al. Increasedprevalence of subclinical coronary atherosclerosis detected by coronary computed tomography angiography in HIV-infected men. AIDS 2010; 24:243-53.
14. Burdo TH, Lo J, Abbara S, et al. Soluble CD163, a novel marker of activated macrophages, is elevated and associated with noncalcified coronary plaque in HIVinfected patients. J Infect Dis 2011; 204: 1227-36.
15. Crowe SM, Westhorpe CL, Mukhamedova N, Jaworowski A, Sviridov D, Bukrinsky M. The macrophage: The intersection between HIV infection and atherosclerosis. J Leukoc Biol 2010; 87:589-98.
16. Martin GE, Gouillou M, Hearps AC, et al. Age-associated changes in monocyte and innate immune activation markers occur more rapidly in HIV infected women. PLoS One 2013; 8:e55279.
17. Hsue PY, Hunt PW, Schnell A, et al. Role of viral replication, antiretroviral therapy, and immunodeficiency in HIV-associated atherosclerosis. AIDS 2009; 23:1059-67.
18. Pereyra F, Lo J, Triant VA, et al. Increased coronary atherosclerosis and immune activation in HIV-1 elite controllers. AIDS 2012; 26:2409-12.
19. Lai S, Fishman EK, Lai H, et al. Long-term cocaine use and antiretroviral therapy are associated with silent coronary artery disease in African Americans with HIV infection who have no cardiovascular symptoms. Clin Infect Dis 2008; 46:600-10.
20. Lai S, Lima JA, Lai H, et al. Human immunodeficiency virus 1 infection, cocaine, and coronary calcification. Arch Intern Med 2005; 165:690-5.
21. Lai S, Bartlett J, Lai H, et al. Long-term combination antiretroviral therapy is associated with the risk of coronary plaques in African Americans with HIV infection. Aids Patient Care STDS 2009; 23:815-24.
22. Schwartz BG, Rezkalla S, Kloner RA. Cardiovascular effects of cocaine. Circulation 2010; 122:2558-69.